Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Korea, republic of
  4. Korea Stock Exchange
  5. Seegene, Inc.
  6. News
  7. Summary
    A096530   KR7096530001

SEEGENE, INC.

(A096530)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Seegene : Unveils Fully Automated Molecular Testing System at the 2021 AACC

09/27/2021 | 07:01am EST
  • Seegene unveils its first fully automated MDx system, STARlet-AIOS: All-in-One System at the 2021 AACC held in the Atlanta, GA, United States
  • AIOS is the MDx system that integrates Seegene's liquid handler and real-time PCR instruments.
  • Seegene MDx system will efficiently access a wide array of Seegene's syndromic assays.

SEOUL, South Korea, Sept. 27, 2021 /CNW/ -- Seegene Inc. (KQ 096530), a leading biotechnology firm specializing in molecular diagnostics, is unveiling a fully automated PCR testing (MDx) system at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo to be held on September 26-30, 2021, in Atlanta, GA, USA.

The AACC is a premier exposition for clinical laboratory products and services with 73 years of history. This global event invites players of major laboratory medicine community including 700 global IVD companies. Seegene also has participated in this event since 2007 along with other global IVD companies.

During this event, Seegene will be unveiling AIOS - its first fully automated MDx system. AIOS provides high-throughput real-time PCR workflow starting from nucleic acid extraction, then, real-time PCR, and finally result interpretation. AIOS is fully automated syndromic MDx system designed in a modular concept while it compiles Seegene's cutting-edge high multiplex real-time PCR technologies.

A noteworthy feature of AIOS is that its MDx system is composed of independent and detachable modules together with its proprietary SW architecture. Unlike others' single-body system, AIOS is designed with an extraction/liquid handler and PCR instrument being integrated with an in-house developed robotic arm module. Hospitals and laboratories can either purchase the full package of 'AIOS' system or integrate their existing instruments on site if they already have Seegene's liquid handler and real-time PCR instrument.

Some of the other highlights include: 'high-throughput automated syndromic MDx system'. It also adopts a variety of Seegene's assays, that are currently available on the market, which allows for symptom-based tests. And finally, it can identify the exact cause of a specific symptom with a single tube, which will enable both cost- and time- effective tests. Therefore, Seegene added that AIOS will be affordable to small-to-medium sized hospitals due to its unique modular and assay features.

"AIOS represents Seegene's decades-long commitment to developing cutting-edge technologies in the molecular diagnostics field," said Dr. Jong-Yoon Chun, CEO of Seegene, "I believe AIOS will contribute to the public health by making MDx more accessible in everyday life."

Cision
View original content to download multimedia:https://www.prnewswire.com/news-releases/seegene-unveils-fully-automated-molecular-testing-system-at-the-2021-aacc-301385449.html

SOURCE Seegene Inc.

© Canada Newswire, source Canada Newswire English

All news about SEEGENE, INC.
11/30Seegene's High Multiplex Pcr Assay Capable of Detecting New Omicron Variant
CI
11/30Seegene's High Multiplex PCR Assay Capable of Detecting New Omicron Variant
AQ
11/23Seegene Announces Q3 2021 Earnings, Continuing COVID-Era Momentum
AQ
11/15Seegene Opens New Subsidiary in Bogotá, Colombia, to Advance Regional COVID-19 Testing
AQ
11/15Seegene Opens New Subsidiary in Bogot?, Colombia, to Advance Regional COVID-19 Testing
CI
11/15Seegene, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended Sept..
CI
10/27SEEGENE INC. ANNOUNCES LAUNCH OF STA : All-in-One System Fulfills Critical Need for Fully ..
CI
10/27LAUNCH OF SEEGENE'S STARLET-AIOS : All-in-One System Fulfills Critical Need for Fully Auto..
AQ
09/28Seegene, Inc.'s Equity Buyback announced on March 9, 2021, has expired.
CI
09/27SEEGENE : Unveils Fully Automated Molecular Testing System at the 2021 AACC
AQ
More news
Financials
Sales 2021 1 256 B 1,06 B 1,06 B
Net income 2021 465 B 0,39 B 0,39 B
Net cash 2021 550 B 0,47 B 0,47 B
P/E ratio 2021 7,46x
Yield 2021 1,47%
Capitalization 3 434 B 2 920 M 2 909 M
EV / Sales 2021 2,30x
EV / Sales 2022 3,23x
Nbr of Employees 985
Free-Float 68,0%
Chart SEEGENE, INC.
Duration : Period :
Seegene, Inc. Technical Analysis Chart | A096530 | KR7096530001 | MarketScreener
Technical analysis trends SEEGENE, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 66 300,00 KRW
Average target price 79 000,00 KRW
Spread / Average Target 19,2%
EPS Revisions
Managers and Directors
Jong-Yoon Chun Chief Executive Officer & Director
Jung-Yong Kim Director & Head-Finance
Hong-Il Yoon Independent Director
Chang-Se Lee Independent Director
Kyung-Jun Chun Director
Sector and Competitors
1st jan.Capi. (M$)
SEEGENE, INC.-31.30%2 920
EXACT SCIENCES CORPORATION-39.19%13 834
GUARDANT HEALTH, INC.-24.22%9 928
BGI GENOMICS CO., LTD.-27.85%5 947
ADAPTIVE BIOTECHNOLOGIES CORPORATION-55.64%3 555
INVITAE CORPORATION-62.31%3 538